Shares of eye care company Alcon AG are trading higher on Monday.

The company has agreed to acquire LENSAR ( LNSR ) Inc , a firm recognized for its laser solutions in cataract surgery.

Under the terms of the deal, Alcon ( ALC ) will purchase LENSAR ( LNSR ) shares for $14.00 per share in cash for an aggregate implied value of approximately $356 million. The deal also an additional non-tradeable contingent value right offering up to $2.75 per share in cash, conditioned on the achievement of 614,000 cumulative procedures with LENSAR’s products between January 1, 2026, and December 31, 2027. The transaction represents a total consideration of up to approximately $430 million.

Also Read: James Hardie To Acquire AZEK In $8.75 Billion Deal, Expanding Its Grip On Outdoor Living Market

The transaction is set to close by mid-to-late 2025, pending regulatory and shareholder approvals. Alcon ( ALC ) held $1.7 billion in cash and equivalents as of December 31, 2024.

“We are excited for the opportunity to bring LENSAR’s unique next-generation technologies and intellectual property into our innovative, market-leading equipment portfolio,” said Alcon ( ALC ) CEO David Endicott.

“By leveraging our global footprint, we have the opportunity to deliver the benefits of advanced femtosecond laser technology to many more surgeons around the world and continue to improve efficiency in cataract surgery.”

The acquisition will expand Alcon’s femtosecond laser-assisted cataract surgery (FLACS) offerings by integrating LENSAR’s ALLY Robotic Cataract Laser System, Streamline software, and additional laser technologies.

The system aims to reduce reliance on blade incisions while improving surgical outcomes, particularly in managing astigmatism and other complex cataract conditions.

Currently, there are more than 5 million cataract procedures in the U.S. and approximately 32 million globally.

Price Action: ALC stock traded higher by 1.91% at $92.29 while LNSR is down 2.40% at $14.47 at last check Monday.

Read Next:

Why Is DNA Test Provider 23andMe Stock Tumbling Today?

Image via Shutterstock.